2-(9-methyl-2,10-dioxo-1,3,9-triazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-3-yl)-N-[(2S)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide | 1123757-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-(9-methyl-2,10-dioxo-1,3,9-triazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-3-yl)-N-[(2S)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
• CAS: 1123757-58-3
• 化学式: C₂₇H₂₂N₆O₄
• 分子量: 494.509
• InChiKey: GOLKXHILZFSODR-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  37
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (2S)-5-amino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 、 2-(9-Methyl-2,10-dioxo-1,3,9-triazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-3-yl)acetic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以76%的产率得到2-(9-methyl-2,10-dioxo-1,3,9-triazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-3-yl)-N-[(2S)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
  参考文献：
  名称：

  The discovery of highly potent CGRP receptor antagonists

  摘要：

  Rational modification of a previously identified spirohydantoin lead structure has identified a series of potent spiroazaoxindole CGRP receptor antagonists. The azaoxindole was found to be a general replacement for the hydantoin that consistently improved in vitro potency. The combination of the indanylspiroazaoxindole and optimized benzimidazolinones led to highly potent antagonists (e.g., 25, CGRP K(i) = 40 pM). The closely related compound 27 demonstrated good oral bioavailability in dog and rhesus. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.106

文献信息

• The discovery of highly potent CGRP receptor antagonists
  作者：Craig A. Stump、Ian M. Bell、Rodney A. Bednar、Joseph G. Bruno、John F. Fay、Steven N. Gallicchio、Victor K. Johnston、Eric L. Moore、Scott D. Mosser、Amy G. Quigley、Christopher A. Salvatore、Cory R. Theberge、C. Blair Zartman、Xu-Fang Zhang、Stefanie A. Kane、Samuel L. Graham、Joseph P. Vacca、Theresa M. Williams

  DOI：10.1016/j.bmcl.2008.10.106

  日期：2009.1

  Rational modification of a previously identified spirohydantoin lead structure has identified a series of potent spiroazaoxindole CGRP receptor antagonists. The azaoxindole was found to be a general replacement for the hydantoin that consistently improved in vitro potency. The combination of the indanylspiroazaoxindole and optimized benzimidazolinones led to highly potent antagonists (e.g., 25, CGRP K(i) = 40 pM). The closely related compound 27 demonstrated good oral bioavailability in dog and rhesus. (C) 2008 Elsevier Ltd. All rights reserved.